Accueil
Explorer
nav.journalClub
Tendances
Plus
synapse
⌘+K
Langue
Français
Français
Impact of Essential Medicines List inclusion on rituximab utilisation in MS and NMOSD patients: A retrospective study | Synapse
March 3, 2026
Impact of Essential Medicines List inclusion on rituximab utilisation in MS and NMOSD patients: A retrospective study
LR
Laavanya Rajendhiran
SS
Shridevi Subramaniam
SV
Shanthi Viswanathan
See all
Key Points
Rituximab utilization in patients increased significantly after inclusion on the essential medicines list.
The retrospective analysis showed a notable rise of approximately 30% in rituximab use among targeted populations.
Data was collected and analyzed from a medical registry spanning several treatment centers over three years.
This analysis highlights the potential impact of policy changes on access to vital therapies, needing further exploration.
Mark Helpful
Like
Save
Bookmark
Relay
Share
Mark Helpful
Like
Save
Bookmark
Relay
Share
Cite This Study
Copy
Rajendhiran et al. (Mon,) studied this question.
synapsesocial.com/papers/69a75f95c6e9836116a2b0d2
https://doi.org/https://doi.org/10.1016/j.jns.2025.124802